A B S T R A C T The purpose of this study was to examine the molecular parameters necessary for initiation of complement fixation by IgM proteins. To determine why some IgM molecules are capable of complement fixation while others are not, several different Waldenstr6m IgM proteins were examined for their ability to fix total hemolytic complement in the CH50 assay. Subsequently, the Cl fixing ability of a 56-residue fragment derived from the C,u4 domain of each of these IgM molecules was studied with the Cl fixation assay.
One of the three Waldenstr6m IgM proteins (Gr) used in the present study was found unable to consume complement in a CH50 assay when tested at the same concentration as the two complement-consuming IgM molecules (Dau and Bus). However, when the 56-residue CH4 fragment from the CjA4 domain of each IgM molecule was tested for Cl-fixing ability, all three were found to bind Cl.
On the basis of these observations, it is proposed that a C1 binding site exists within the C,U4 domain of both complement-fixing and noncomplement-fixing IgM molecules. Presumably, the latter molecules are unable to interact in their native state with Cl in the manner required for initiation of the classical complement pathway, possibly due to the configurational inaccessibility of the entire C1 binding site.
INTRODUCTION
There have been several reports in the literature suggesting the existence of two IgM subclasses, one capable of fixing complement and the second consisting of noncomplement-fixing IgM antibodies (1) (2) (3) (4) . In one such study Onoue and Ikeda (3) reported the identification of three noncomplement-fixing Waldenstrom IgM proteins out of a group of six. In a more recent publication, Tanimoto, et al. (4) reported that whereas a group of three monoclonal IgM-rheumatoid factor molecules were found to lack complement-fixing activity in a direct hemolytic assay system, three polyclonal rheumatoid factors were found capable of fixing and activating complement via the classical pathway. These authors suggested that IgM-rheumatoid factor may be composed of a mixture of complement-fixing and noncomplement-fixing antibodies, the noncomplement-fixing IgM A detailed account of these methodologies and characterization of the fragments obtained from Gr IgM has been published by Hester et al. (7) . The fragments isolated from Dau and Bus IgM molecules behaved identically to the Gr fragments during both fractionation and characterization.
After centrifugation for 1 h at 100,000 g, protein concentrations were determined spectrophotometrically at 280 nm with E'm of 12.0 for IgM and for (Fc)s,u. The CE4 fragments were desalted in 1% NH4HCO3, lyophilized, and weighed directly. A measured aliquot of the parent stock solution of each CH4 fragment was removed for quantitative amino acid analysis.
Amino acid analyses. Samples were hydrolyzed in constantly boiling HCl in vacuum-sealed tubes for 20 h. After evaporation, the samples were analyzed on a Durrum model D-200 automatic amino acid analyzer with high-speed analysis and the single-column technique (Durrum Instrument Corp., Palo Alto, Calif.).
Gel electrophoresis. Disc electrophoresis was performed with 5% polyacrylamide, as described by Maizel (9) . The gels were run in 0.1 M sodium phosphate buffer (pH 7.2) containing 0.1% sodium dodecyl sulfate and 0.5 M urea, stained for 15-30 min with 1% amido black (Gallard-Schlesinger Chemical Mfg. Co., Carle Place, N. Y.) in 7% acetic acid, and destained in 40% absolute methanol and 10% acetic acid.
Buffers used in complement assays. Gelatin-veronal buffer is barbital-buffered saline (VBS)l containing 0.1% gelatin, 0.15 mM CaCI2, and 1 mM MgCl2, with a relative salt concentration of 0.15. The relative salt concentration of each buffer was monitored by relating the electrical resistance of the buffer at 0°C to a standard curve obtained by graphing the resistance of NaCl solutions vs. the NaCl molarities (10).
1 Abbreviation used in this paper: VBS, veronal-buffered saline.
Dextrose-gelatin VBS++ is VBS diluted with 5% dextrose to a relative salt concentration of 0.075, containing standard amounts of gelatin, Ca++, and Mg++ (11) . Dextrose VBS++, the buffer used for dilution of immunoglobulin and its fragments, refers to dextrose-gelatin VBS minus the gelatin. VBS containing 0.02 M EDTA and 0.1% gelatin (EDTA-gelatin-VBS) was also used as a buffer in the complement assays (11) .
Complement components and intermediates. Partially purified human Ci and guinea pig C2 were prepared as described by Nelson et al. (12) . EAC4hu (sheep erythrocytes sensitized with rabbit antibody to E, to which complement components have been added) were made by a slight modification of the method described by Borsos and Rapp (13), using guinea pig (gp) Cl (7) found that total reduction of Gr monomeric Fc,u released four SH groups per fragment, indicating that the two intrachain disulfide loops had remained intact.
The Fc, fragment was treated with trypsin for 16 min at 37°C and the digest passed through a Sephadex G-75 column in 5 M guanidine-HCl (7). The peak containing the CH4 fragments was pooled, desalted on Sephadex G-25 in 1% NH4HCO3, lyophilized, and applied to a Bio-Gel P-10 column in 5 M guanidineHCl. After elution from the P-10 column, the CR4 fragments from each of the IgM proteins gave a single band on 5% sodium dodecyl sulfate acrylamide gels.
The gel filtration patterns and fragment analyses obtained during the fragmentation of Gr IgM have been published by Hester et al. (7) . Similar patterns and products resulted from the fragmentation of Dau and Bus IgM molecules. Partial sequence analysis and a comparison of the amino acid composition of the Gr CH4 fragment and of its respective isolated peptide chains with that published for the IgM, For the final set of experiments, the CH4 fragment was isolated from Dau, Bus, and Gr IgM proteins and tested in the C1 fixation assay (Table III) . It was found that the CR4 fragment from each of these IgM molecules was able to fix Cl, with 8 jtg of Dau and Bus CR4 fragments and 24,Ug of Gr CH4 fragment required to fix one-half of the available C1. Fig. 1 is a graph of these results. It should be noted that although the Gr CH4 fragment appears to be slightly less efficient than the Dau and Bus CH4 fragments in binding Cl, the molar ratios for the three fragments are of the same order of magnitude. (17) that certain repeating regions of immunoglobulin polypeptide chains are folded into compact globular structures called domains, each evolved to perform a particular biologic function. According to this concept, it should be possible to associate specific biological effector functions, such as complement fixation, with a specific submolecular domain in certain immunoglobulin molecules. Evidence to support this hypothesis has been obtained from the data of Connell and Porter (18) and of Ellerson et al. (19) demonstrating that the C"y2 domain of IgG contains a C1 binding site (Fig. 2 ) and (6) On the basis of these data, and the observation that upon incubation with normal human serum the CH4 fragment consumes C4 (16) , it is proposed that a classical complement fixation function, i.e., Cl binding and activation, can be localized within the C,U4 domain of the IgM molecule (Fig. 2) .
The sequence data presented by Florent et al. (6) indicate that only minor differences exist in the primary structure of the Fc region of both pathological and normal IgM molecules. This being true, it follows that if primary structure relates directly to function, the CH4 fragment from complement-fixing and from noncomplement-fixing molecules should possess Cl fixing ability. Whether or not each respective IgM could fix C1 so that it could subsequently interact with the other early complement components would therefore depend upon the relative exposure of the C,4 domain in the intact molecule. This was indeed borne out by the fact that the isolated CH4 fragment from the noncomplement-fixing IgM, Gr, was able to fix C1, and did so nearly as efficiently as the CH4 fragments from the complement-fixing IgM molecules, Dau and Bus. The threefold difference in Cl-fixing ability observed between the CH4 fragments from complement-fixing and noncomplement-fixing molecules was not felt to be significant.
That the CH4 fragments from two complement-fixing IgM molecules (Dau and Bus) and from an apparent noncomplement-fixing IgM protein (Gr) were each capable of Cl fixation raises interesting possibilities.
In this regard it should be pointed out that Isenman et al. (22) found that while noncomplement-fixing IgG4 does not bind CI, Fc fragments derived from this subclass do fix C1, and do so with an affinity comparable to the corresponding fragment from IgGi. In an earlier publication these authors reported that the Cl fixing site of 12-microglobulin remains active after reduction and alkylation (23) . Furthermore, they obtained spectral data indicating that in the absence of an intact intrachain disulfide bond, f32-microglobulin does not fold into the conformation characteristic of the native state. On the basis of these data Isenman and coworkers postulated that little secondary or tertiary folding is required for the existence of an active Cl binding site, and that the chemical features of the linear amino acid sequence required for binding of C1 may be commonplace but may be prevented from reacting because of local folding patterns or interaction with one-dimensionally distant regions of the molecule (22) . Such an interpretation is consistent with our observation that fragments derived from the C,u4 domain of both complement-fixing and noncomplement-fixing IgM molecules retain the ability to fix C1.
Considering our data on IgM relative to that of Isenman and colleagues on IgG4 and /32-microglobin, we suggest that a C1 fixing site may exist in all IgG and IgM proteins, the noncomplement-fixing molecules possessing configurations that interfere with correct C1 binding.
